Navigation Links
FDA Gives Nod to New Breast Cancer Drug
Date:7/21/2012

FRIDAY, July 20 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved the use of the drug Afinitor (everolimus) for use by women with a particular form of advanced breast cancer.

It's the first time that a drug from this class of medications, called mTOR inhibitors, has been approved for this disease, the FDA said. Afinitor is already used to fight advanced kidney and neuroendocrine tumors, as well as a handful of rarer cancers.

The medicine is only approved for use by postmenopausal women battling an advanced form of estrogen-sensitive tumor known as hormone-receptor positive, HER2-negative breast cancer. Even then, Afinitor should only be used after such patients have already experienced a recurrence or progression of the tumor following prior treatment with Femara (letrozole) or Arimidex (anastrozole), the FDA said.

Adding Afinitor -- which has proven effective for other cancers -- to therapy might help these patients, the agency said.

"Afinitor is another example of the value of continuing to study drugs in additional types of cancer after their initial approval," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

According to the FDA, approval was based on a clinical trial involving 724 postmenopausal women with advanced breast cancer that had spread despite prior treatment with Femara or Arimidex. All of the women also took the standard breast cancer drug Aromasin (exemestane) during the trial.

The trial found that adding in Afinitor boosted average progression-free survival (the time the women lived without any progression of their tumor) by 4.6 months compared to women taking an inactive placebo.

There was a downside to using Afinitor, however: According to the FDA, side effects included rash, fatigue, diarrhea, loss of appetite and mouth ulcers. T
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. U.S. Gives Green Light to Publish Controversial Bird Flu Research
2. Image share project gives patients and physicians anytime, anywhere access to medical images
3. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
4. UMD team gives drug dropouts a second chance
5. FDA Panel Gives Blessing to New Weight-Loss Drug
6. Amazon Tribe Gives Clues to Heart-Healthy Lifestyles
7. Killer stainless steel: New process gives icon of cleanliness antibacterial coating
8. Aurora Dentist Gives Patients Big Savings With Teeth in a Day Implants
9. OC Firm Gives Back to Young Athletes
10. Study Gives First Evidence That Adult Human Lungs Can Regrow
11. Eliminating the good cholesterol receptor may fight breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Gives Nod to New Breast Cancer Drug
(Date:6/3/2015)... Accountable care organizations (ACOs) are increasingly partnering ... worries that these product types were too similar to ... that product-based ACOs will continue to grow in size ... June issue of Atlantic Information Services, Inc.’s (AIS) AIS’s ... that the backlash from HMOs seems to be fading ...
(Date:6/3/2015)... 2015 Loma Linda University Health and ... San Gorgonio Memorial Hospital (SGMH). The SGMH board voted ... 28. , “Loma Linda University Health has been serving ... chief executive officer, Loma Linda University Medical Center. “We ... services to this community.” , Under the proposed ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 The Canton ... transforms businesses with technology, announced today that Tim Dodge ... Mr. Dodge joins The Canton Group as ... of successful customer engagements. , Tim is a tech ... for a variety of technology companies. Before joining The ...
(Date:6/3/2015)... WA (PRWEB) June 03, 2015 On June ... the majority of genetic drug sensitivity (pharmacogenetic) testing that it ... to impact as many as 19 million of the 49 ... risk of costly and life-threatening adverse drug events.(1) Sadly, if ... Medicare millions. , Precision Medicine, the use of an individual’s ...
(Date:6/3/2015)... Horizon Blue Cross Blue Shield of New Jersey has ... nation’s top employers for diverse managers and women. The ... of Best Places for Diverse Managers and Women to Work ... This is the sixth consecutive year that Horizon BCBSNJ ... workplace policies and programs. , Companies are selected based on ...
Breaking Medicine News(10 mins):Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 3Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2
... 31, 2008) Patients treated at top-rated hospitals ... on average, than those admitted to all other ... HealthGrades, the leading independent healthcare ratings organization. Patients ... have an average five percent lower risk of ...
... arthritis (RA), an inflammatory autoimmune disease, tend to ... One explanation for this increasingly recognized fact ... of inflammation, elevation of the C-reactive protein (CRP) ... the general population. However, other highly inflammatory ...
... Charity Care Required in Favored, Neighborhoods - New Information Strengthens Community,s Demand ... ... OAKLAND, Calif., Jan. 30 Sutter Health told the San,Francisco Chronicle ... offer dramatically less charity care than St. Luke,s,Hospital, the South of Market ...
... Low-income children to benefit from annual Give Kids ... February is National Children,s Dental,Health Month and on ... free dental services to more than 500,000 children ... It,s all part of the,American Dental Association,s (ADA) ...
... Event ... City, NEW YORK, Jan. 30 Woman,s Day magazine,s 5th ... four women who,have made significant contributions to the fight against heart ... Spencer will emcee the event on Thursday, January,31st at the Stone ...
... Adults with allergy symptoms report a high incidence of ... disorders and IBS according to a study published this ... scientific journal of the American Collegeof Allergy, Asthma and ... University Medical Center,s Dr. Mary C. Tobin and colleagues ...
Cached Medicine News:Health News:Top hospitals have 27 percent lower mortality, annual HealthGrades study finds 2Health News:Top hospitals have 27 percent lower mortality, annual HealthGrades study finds 3Health News:The HLA-DRB1 gene and premature death in rheumatoid arthritis 2Health News:The HLA-DRB1 gene and premature death in rheumatoid arthritis 3Health News:Open Wide! Nation's Dentists Address Access With Free Care for Kids 2Health News:Open Wide! Nation's Dentists Address Access With Free Care for Kids 3Health News:Woman's Day Presents the 5th Annual 'Red Dress Awards' Honoring Women Who Are Leaders in the Fight Against Heart Disease 2Health News:Woman's Day Presents the 5th Annual 'Red Dress Awards' Honoring Women Who Are Leaders in the Fight Against Heart Disease 3Health News:Woman's Day Presents the 5th Annual 'Red Dress Awards' Honoring Women Who Are Leaders in the Fight Against Heart Disease 4
(Date:6/3/2015)... -- Varian Medical Systems (NYSE: VAR ), world leader in ... in the Middle East with the ... Arabia . Varian Medical Systems Arabia, the result of ... launched today at a ceremony attended by local dignitaries and ... move represents the next step in our commitment both to ...
(Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/snzzg5/2015_strategies ... "2015 Strategies in the US Tumor Marker Testing ... Highlights of the Report Include , ... testing market. , Major issues pertaining to ... economic, regulatory, demographic, social and technological trends with ...
(Date:6/3/2015)... 3, 2015 Creekridge Capital, an independent, national ... channels by adding two new sales representatives. Sam ... Sales Manager and Stefanie Stark joined the ... comes to Creekridge with over 20 years of vendor ... Creekridge, Mr. Puma will be responsible for identifying, implementing ...
Breaking Medicine Technology:Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2Creekridge Capital Strengthens Sales Team 2
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
... percent response rate achieved with VELCADE, lenalidomide,and ... -- Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported ... trials of VELCADE based,therapies that showed consistently ... (CR) rates in newly diagnosed,multiple myeloma (MM) ...
Cached Medicine Technology:CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
... workstations is designed for laboratories with limited ... automation platform for routine sample preparation and ... throughput, process consistency and safety. Windows ... you to control the robotic and liquid ...
... The Labcyte miniGene LD is a ... to 96-, 384- and 1536-well microplates. This ... 16 channel standard or wide orifice nozzle ... movement allow for accurate dispensing to a ...
... The QFill2 is the ideal system for fast, ... The pressure driven, pinch valve controlled dispensing mechanism, ... Whilst all of the components that come into ... dismantle, clean, and autoclave. The unique compact design ...
... an innovative reagent dispenser for plate ... fulfill the need for precise automated ... more, FlexDrop provides an efficient solution ... tedious task of plate preparation for ...
Medicine Products: